HAURAKI PHO
  • Home
  • About us
    • Our People
  • Services We Offer
    • HPHO Practices
    • After Hours Services
    • Breast and Cervical Screening Support
    • Diabetes Management
    • Heart Check
    • Ngā Kaitiaki Manawanui Whai Ora
    • Outreach Immunisation Service
    • Primary Options
    • Patient Portal
    • Primary Mental Health Services
    • Shared Electronic Health Record
  • News & Support
    • Education and Training
    • Coronavirus Updates >
      • COVID-19 Vaccine Updates
    • Join the Team!
  • Hauraki Locality
  • Contact
  • Home
  • About us
    • Our People
  • Services We Offer
    • HPHO Practices
    • After Hours Services
    • Breast and Cervical Screening Support
    • Diabetes Management
    • Heart Check
    • Ngā Kaitiaki Manawanui Whai Ora
    • Outreach Immunisation Service
    • Primary Options
    • Patient Portal
    • Primary Mental Health Services
    • Shared Electronic Health Record
  • News & Support
    • Education and Training
    • Coronavirus Updates >
      • COVID-19 Vaccine Updates
    • Join the Team!
  • Hauraki Locality
  • Contact

Amgevita (biosimilar adalimumab) funded from 1 March 2022

23/2/2022

 
In November 2021 we announced the decision to widen access to adalimumab and award Principal Supply to Amgevita, a citrate-free biosimilar adalimumab. Amgevita will be listed in the Pharmaceutical Schedule from 1 March 2022.
 
What does this change mean
From 1 March 2022, most patients currently using Humira will need to transition to Amgevita.
 
There are some key actions that healthcare professionals can take to support this change.
 
  • Be aware that on 1 March 2022, all people currently using adalimumab will be automatically issued with an initial Special Authority number for Amgevita. Their Humira Special Authority will remain current.
  • Ensure you prescribe adalimumab by brand (either Amgevita or Humira).
  • Identify patients using adalimumab and discuss the continuation of their treatment with Amgevita when their Humira Special Authority is due for renewal, or before 1 October 2022.
  • Go to amgevita.co.nz for resources to support you and your patients with this change.
  • Go to the Pharmac website for information about the changes to funding criteria for Humira.​
continued...
More information
You can find more information about this change, and what it means for you, on the Pharmac website.
 
Resources are available to support you and your patients with this change:
He Ako Hiringa: Biological Medicines Resource Hub
He Ako Hiringa: Transition to adalimumab biosimilar
 
More resources will be released in the coming weeks. We will continue to update the Pharmac website with links to resources to support this change as they become available.

Please share this information
We want to make sure everyone who needs to know about these changes is aware of them. Please share this information with your colleagues. 
 
We want to extend our thanks to you and your colleagues for supporting people with this change.

Click here for the mailer


Ngā mihi nui,
Chief Medical Officer | Tumu Whakarae Haumanu
Pharmac


Comments are closed.

    Author

    Write something about yourself. No need to be fancy, just an overview.

    Archives

    October 2022
    August 2022
    July 2022
    March 2022
    February 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020

    Categories

    All

    RSS Feed

THAMES
106 Sealey Street, Thames 3500
phone 07-868-9686
Send us a message
HAMILTON
​16 Patikitiki​ Street, Hamilton East
​Hamilton 3216

phone 07-868-9686
Send us a message
Picture
Copyright © Hauraki Primary Health Organisation  |  2020